August 29, 2012 / 6:16 AM / 7 years ago

Russia's Pharmstandard H1 earnings down 27 pct

MOSCOW, Aug 29 (Reuters) - Pharmstandard, Russia’s top drugmaker, posted on Wednesday a 27 percent fall in first-half net profit to 3.07 billion roubles ($95.89 million), slightly below a 3.19 billion rouble analyst forecast.

Pharmstandard also said in a statement its fist half earnings before interest, taxation, depreciation and amortisation (EBITDA) amounted to 4.13 billion roubles, below a 4.55 billion rouble forecast.

The company earlier reported a 13.3 percent fall in first-half revenues to 16.2 billion roubles due to weaker sales of anti-flu drugs and changes in regulation of distribution of codeine-containing medication.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below